// App-Quantinova.ai

Mo1790 : Safety, Efficacy, and Pharmacokinetics of Golimumab in Patients with Moderately to Severely Active Ulcerative Colitis: PURSUIT-SC Long term Extension

Researchers

Presenter

  • Peter R. Gibson

Principal Investigators

  • William Sandborn

  • Judith Collins

  • Paul J. Rutgeerts

  • Dino Tarabar

  • Brian G. Feagan

  • Colleen Marano

  • Rick Strauss

  • Jewel Johanns

  • Hongyan Zhang

  • Lakshmi Padgett

  • Omoniyi J. Adedokun

  • Jean-Frederic Colombel

Medical Centers

  • Military Medical Academy, Belgrade, Serbia

  • Alfred Hospital, Melbourne, NorthWest Territories, Canada

  • University Hospital Gasthuisberg, Leuven, Belgium

  • UC Davis, Davis, California, United States

  • Robarts Reserach Institute, London, ON, Canada

  • Universitatsklinik fur Innere Medizin III and McMaster University, Vienna and Hamilton, Austria

  • Icahn School of Medicine at Mount Sinai, New York, New York, United States

  • Oregon Health and Science University, Portland, Oregon, United States

Locations

  • Canada

  • Austria

  • United States

  • Serbia

  • Belgium

Companies

  • Janssen Global Servi

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Gallbladder cancer

  • Ulcerative colitis

  • Bladder Cancer

  • Colorectal Cancer

  • Solid malignancies

  • Lymphomas

  • Sepsis

Biomarkers

  • N/A

Drug/Treatment

  • golimumab

Outcome

  • Unknown

Study Design

  • randomized

  • pharmacokinetics

  • cross over

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved